India's diagnostics market shifts to preventive, precision testing in 2025

India's diagnostics sector is seeing a strong shift towards preventive and precision-led testing in 2025, driven by rising demand for proactive health checks and faster genomic diagnostics

Diagnostic labs, which began increasing prices since last year after a long halt due to competition from online players, have seen improvement in margins as a result.
Industry experts note that these tests are increasingly being used to detect chronic and underlying health conditions at an earlier stage | Representative Picture
Anjali Singh Mumbai
2 min read Last Updated : Dec 24 2025 | 6:13 PM IST
India’s diagnostics sector is seeing a marked shift toward preventive and precision-led testing, with consumers increasingly opting for proactive health checks over symptom-driven diagnostics, according to year-end data released by Agilus Diagnostics.
 
Preventive health testing grew 30 per cent year-on-year (Y-O-Y) in 2025, indicating rising awareness around early monitoring of metabolic health, cardiovascular risk and nutritional status. The trend is most visible among urban populations, particularly younger adults in cities such as Mumbai, Delhi NCR, Bengaluru, Kolkata, Lucknow and Chandigarh.
 
Lifestyle and gut health diagnostics recorded even faster growth, with testing volumes rising 47 per cent year-to-date, compared with 31 per cent growth last year. Tests related to microbiome analysis, gastrointestinal health, pancreatic function and food intolerance are seeing higher adoption, driven by changing dietary habits, sedentary lifestyles and increased clinical recommendations.
 
Industry experts note that these tests are increasingly being used to detect chronic and underlying health conditions at an earlier stage, making routine screening more common.
 
Precision oncology diagnostics also showed steady growth during the year. Oncogenomics testing volumes rose 16 per cent year-to-date, supported by improvements in turnaround times. Genomic results for blood cancers are now available within three days, while comprehensive profiling for solid tumours is being delivered within five days. Faster reporting timelines are enabling clinicians to take quicker treatment decisions based on molecular-level insights.
 
The shift reflects broader changes in how individuals engage with healthcare placing greater emphasis on prevention, risk assessment and data-driven decision-making.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :DiagnosticsDiagnosticHealth Check

Next Story